14 November, 2022 in Investor Relations Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
20 September, 2022 in Investor Relations Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering
15 September, 2022 in Investor Relations Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering
